{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T07:45:32Z","timestamp":1791963932262,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.09.010","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:31:37Z","timestamp":1790098297000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Need for population-specific lipid guidelines for South Asians: Focus on the Indian population and its distinct cardiometabolic risk profile"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0234-6366","authenticated-orcid":false,"given":"Raman","family":"Puri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3762-2618","authenticated-orcid":false,"given":"Vimal","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasant Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0621-1509","authenticated-orcid":false,"given":"Jamal","family":"Yusuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jacl.2026.09.010_bib1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s11886-026-02355-7","article-title":"Global burden of cardiovascular disease: what should be expected in the next 25 years?","volume":"28","author":"Naeem","year":"2026","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jacl.2026.09.010_bib2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12889-021-10429-0","article-title":"Trend analysis of cardiovascular disease mortality, incidence, and mortality-to-incidence ratio: results from global burden of disease study 2017","volume":"21","author":"Amini","year":"2021","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jacl.2026.09.010_bib3","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/01.CIR.97.6.596","article-title":"Emerging epidemic of cardiovascular disease in developing countries","volume":"97","author":"Reddy","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.09.010_bib4","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1161\/hc4601.099487","article-title":"Global burden of diseases, part 1: general considerations, the epidemiologic transition, risk factors and impact of urbanization","volume":"104","author":"Yusuf","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.09.010_bib5","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1056\/NEJMp048024","article-title":"Cardiovascular diseases in non-Western countries","volume":"350","author":"Reddy","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.09.010_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacl.2020.01.010","article-title":"The epidemic of atherosclerotic cardiovascular disease in India","volume":"14","author":"Duell","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.010_bib7","doi-asserted-by":"crossref","first-page":"e1339","DOI":"10.1016\/S2214-109X(18)30407-8","article-title":"The changing patterns of cardiovascular diseases and their risk factors in the states of India: the Global Burden of Disease Study 1990-2016","volume":"6","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jacl.2026.09.010_bib8","article-title":"The burgeoning cardiovascular disease epidemic in Indians- perspectives on contextual factors and potential solutions","volume":"12","author":"Kalra","year":"2023","journal-title":"Lancet Reg Health Southeast Asia"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.010_bib9","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ihj.2012.07.001","article-title":"Coronary heart disease and risk factors in India- on the brink of an epidemic?","volume":"64","author":"Krishnan","year":"2012","journal-title":"Indian Heart J"},{"key":"10.1016\/j.jacl.2026.09.010_bib10","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/j.jacc.2010.09.083","article-title":"Incidence of cardiovascular risk factors in an Indian urban cohort results from the New Delhi birth cohort","volume":"57","author":"Huffman","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"11[Special]","key":"10.1016\/j.jacl.2026.09.010_bib11","first-page":"6","article-title":"Fighting the atherosclerotic cardiovascular disease epidemic: declaring war on lipids by Lipid Association of India","volume":"68","author":"Mehta","year":"2020","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.jacl.2026.09.010_bib12","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case- control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.010_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.21037\/atm.2017.10.18","article-title":"Asian-Indians: a review of coronary artery disease in this understudied cohort in the United States","volume":"6","author":"Ardeshna","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jacl.2026.09.010_bib14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/jama.297.3.286","article-title":"Risk factors for early myocardial infarction in South Asians compared with individuals in other countries","volume":"297","author":"Joshi","year":"2007","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jacl.2026.09.010_bib15","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/CIRCULATIONAHA.120.052430","article-title":"Quantifying and understanding the higher risk of atherosclerotic cardiovascular disease among South Asian individuals: results from the UK Biobank prospective cohort study","volume":"144","author":"Patel","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.09.010_bib16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1749-6632.2012.06838.x","article-title":"Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations","volume":"1281","author":"Gujral","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jacl.2026.09.010_bib17","unstructured":"IDF Diabetes Atlas. 11th edition, 2025. IDF Diabetes Atlas | Global Diabetes Data & Statistics. https:\/\/diabetesatlas.org\/resources\/idf-diabetes-atlas-2025\/."},{"issue":"4","key":"10.1016\/j.jacl.2026.09.010_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.041221","article-title":"Prevalence and trends in cardiovascular risk factors among middle-aged South Asian adults compared with other racial and ethnic groups in the United States: a longitudinal analysis of 2 cohort studies","volume":"15","author":"Pedamallu","year":"2026","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.010_bib19","first-page":"102","article-title":"Acculturation and subclinical atherosclerosis among U.S. South Asians: findings from the MASALA study","volume":"1","author":"Kanaya","year":"2014","journal-title":"J Clin Exp Res Cardiol"},{"key":"10.1016\/j.jacl.2026.09.010_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001117","article-title":"Association of 10-year and lifetime predicted cardiovascular disease risk with subclinical atherosclerosis in South Asians: findings from the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study","volume":"3","author":"Kandula","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.09.010_bib21","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamainternmed.2017.8094","article-title":"Diabetes and hypertension in India: a nationally representative study of 1.3 million adults","volume":"178","author":"Geldsetzer","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacl.2026.09.010_bib22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/HJH.0000000000000146","article-title":"Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension","volume":"32","author":"Anchala","year":"2014","journal-title":"J Hypertens"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.010_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096808","article-title":"Prevalence of dyslipidemia in urban and rural India: the ICMR\u2013INDIAB Study","volume":"9","author":"Joshi","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jacl.2026.09.010_bib24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"ICMR-INDIAB collaborative study group. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2026.09.010_bib25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000580","article-title":"Atherosclerotic cardiovascular disease in South Asians in the United States: epidemiology, risk factors, and treatments: a scientific statement from the American Heart Association","volume":"138","author":"Volgman","year":"2018","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.010_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5334\/gh.882","article-title":"A comparison of lipids and apo B in Asian Indians and Americans","volume":"16","author":"Singh","year":"2021","journal-title":"Glob Heart"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.010_bib27","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1186\/s12889-025-22625-3","article-title":"Rural-urban differences in lipid abnormalities among middle-aged and older Indians","volume":"25","author":"Chatterjee","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jacl.2026.09.010_bib28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1161\/01.CIR.82.2.495","article-title":"Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk","volume":"82","author":"Austin","year":"1990","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2026.09.010_bib29","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3892\/mmr.2025.13693","article-title":"Small dense LDL: an underestimated driver of atherosclerosis (review)","volume":"32","author":"Bekbossynova","year":"2025","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.jacl.2026.09.010_bib30","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.ATV.19.11.2749","article-title":"Increased prevalence of smaller and denser LDL particles in Asian Indians","volume":"19","author":"Kulkarni","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.010_bib31","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"INTERHEART Investigators. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.010_bib32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ihj.2019.04.007","article-title":"Lipoprotein(a): an underrecognized genetic risk factor for malignant coronary artery disease in young Indians","volume":"71","author":"Enas","year":"2019","journal-title":"Indian Heart J"},{"issue":"14","key":"10.1016\/j.jacl.2026.09.010_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.040361","article-title":"Role of lipoprotein(a) in atherosclerotic cardiovascular disease in South Asian individuals","volume":"14","author":"Patel","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"10.1016\/j.jacl.2026.09.010_bib34","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.jacl.2026.09.010_bib35","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.010_bib36","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.010_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"11[Special]","key":"10.1016\/j.jacl.2026.09.010_bib38","first-page":"42","article-title":"Lipoprotein(a) and ASCVD risk","volume":"68","author":"Puri","year":"2020","journal-title":"J Assoc Physicians India"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.010_bib39","first-page":"1208","article-title":"Pelacarsen: mechanism of action and Lp(a)-lowering effect","volume":"19","author":"Bhatia","year":"2025","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.09.010_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON Trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2026.09.010_bib41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1479-5868-11-26","article-title":"Physical activity and inactivity patterns in India- results from the ICMR-INDIAB study (Phase-1) [ICMR-INDIAB-5]","volume":"11","author":"Anjana","year":"2014","journal-title":"Int J Behav Nutr Phys Act"},{"key":"10.1016\/j.jacl.2026.09.010_bib42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.puhe.2014.12.004","article-title":"Risk factors of overweight and obesity in childhood and adolescence in South Asian countries: a systematic review of the evidence","volume":"129","author":"Mistry","year":"2015","journal-title":"Public Health"},{"issue":"9326","key":"10.1016\/j.jacl.2026.09.010_bib43","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"11[Special]","key":"10.1016\/j.jacl.2026.09.010_bib44","first-page":"21","article-title":"Low density lipoprotein cholesterol targets in secondary prevention of atherosclerotic cardiovascular disease","volume":"68","author":"Puri","year":"2020","journal-title":"J Assoc Physicians India"},{"issue":"25","key":"10.1016\/j.jacl.2026.09.010_bib45","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2026.09.010_bib46","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"lirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacl.2026.09.010_bib47","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"CLEAR Outcomes Investigators. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jacl.2026.09.010_bib48","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology solution set oversight committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.010_bib49","first-page":"7","article-title":"Lipid Association of India expert consensus statement on management of dyslipidemia in Indians 2016: part 1","volume":"64","author":"Iyengar","year":"2016","journal-title":"J Assoc Physicians India"},{"issue":"27","key":"10.1016\/j.jacl.2026.09.010_bib50","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/eurheartj\/ehx710","article-title":"'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies","volume":"39","author":"Annemans","year":"2018","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jacl.2026.09.010_bib51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacl.2020.01.006","article-title":"Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: expert consensus statement from Lipid Association of India","volume":"14","author":"Puri","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"10","key":"10.1016\/j.jacl.2026.09.010_bib52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.59556\/japi.72.0692","article-title":"Does adopting western low-density lipoprotein cholesterol targets expose Indians to a higher risk of cardiovascular events? Expert opinion from the Lipid Association of India","volume":"72","author":"Puri","year":"2024","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.jacl.2026.09.010_bib53","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.09.010_bib54","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk of cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.09.010_bib55","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT Trial","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"18","key":"10.1016\/j.jacl.2026.09.010_bib56","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2026.09.010_bib57","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a pre-specified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.09.010_bib58","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease: an analysis from FOURIER","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2026.09.010_bib59","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.010_bib60","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/j.jacl.2024.01.006","article-title":"Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: consensus statement IV","volume":"18","author":"Puri","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.09.010_bib61","first-page":"1408","article-title":"Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial","volume":"44","author":"Schwartz","year":"2023","journal-title":"Eur Heart J"},{"issue":"8 Pt 2","key":"10.1016\/j.jacl.2026.09.010_bib62","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/j.jacasi.2026.04.020","article-title":"Low-density lipoprotein cholesterol goal attainment in Indian patients with coronary artery disease: a nationwide study","volume":"6","author":"Puri","year":"2026","journal-title":"JACC Asia"},{"key":"10.1016\/j.jacl.2026.09.010_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.101288","article-title":"Cardiovascular disease risk estimates using the new PREVENT equation: the good, bad, and the ugly","volume":"24","author":"Selvam","year":"2025","journal-title":"Am J Prev Cardiol"},{"issue":"7","key":"10.1016\/j.jacl.2026.09.010_bib64","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jacc.2005.07.006","article-title":"The forgotten majority: unfinished business in cardiovascular risk reduction","volume":"46","author":"Libby","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.09.010_bib65","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacl.2022.11.002","article-title":"Management of diabetic dyslipidemia in Indians: expert consensus statement from the Lipid Association of India","volume":"17","author":"Puri","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2026.09.010_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2023.117312","article-title":"Non-HDL-cholesterol in dyslipidemia: review of the state-of-the-art literature and outlook","volume":"383","author":"Raja","year":"2023","journal-title":"Atherosclerosis"},{"issue":"11[Special]","key":"10.1016\/j.jacl.2026.09.010_bib67","first-page":"54","article-title":"Non-HDL cholesterol and atherosclerotic cardiovascular disease","volume":"68","author":"Puri","year":"2020","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.jacl.2026.09.010_bib68","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.amjcard.2012.07.007","article-title":"Meta-analysis of comparison of the effectiveness of lowering apolipoprotein B versus low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol for cardiovascular risk reduction in randomized trials","volume":"110","author":"Robinson","year":"2012","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.010_bib69","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/CIRCULATIONAHA.124.068885","article-title":"Apolipoprotein B: bridging the gap between evidence and clinical practice","volume":"150","author":"De Oliveira-Gomes","year":"2024","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacl.2026.09.010_bib70","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/0091270009334376","article-title":"Statin effects on LDL and HDL cholesterol in South Asian and white populations","volume":"49","author":"Gupta","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.jacl.2026.09.010_bib71","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.amjcard.2007.01.028","article-title":"Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS trial)","volume":"99","author":"Deedwania","year":"2007","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.010_bib72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.59556\/japi.74.1444","article-title":"Early LDL-C lowering efficacy of high-intensity atorvastatin and ezetimibe combination compared with high-intensity atorvastatin alone in acute coronary syndrome: the LAI EARLY ACS Study","volume":"74","author":"Mehta","year":"2026","journal-title":"J Assoc Physicians India"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.010_bib73","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1016\/j.jacl.2024.06.001","article-title":"Rapid achievement of low-density lipoprotein cholesterol goals within 1 month after acute coronary syndrome during combination therapy with rosuvastatin, ezetimibe and bempedoic acid: initial experience from the LAI-REACT study","volume":"18","author":"Mahajan","year":"2024","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.jacl.2026.09.010_bib74","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1253\/circj.CJ-20-1051","article-title":"Efficacy and safety of long-term evolocumab use among Asian subjects- a subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial","volume":"85","author":"Keech","year":"2021","journal-title":"Circ J"},{"issue":"9374","key":"10.1016\/j.jacl.2026.09.010_bib75","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2026.09.010_bib76","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacl.2026.09.010_bib77","doi-asserted-by":"crossref","first-page":"80","DOI":"10.59556\/japi.72.0614","article-title":"Navigating cardiovascular risk and lipid management in Indian patients: key messages from the Lipid Association of India 2024 consensus statement IV","volume":"72","author":"Puri","year":"2024","journal-title":"J Assoc Physicians India"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:54:13Z","timestamp":1791960853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426005210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":77,"alternative-id":["S1933287426005210"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.010","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Need for population-specific lipid guidelines for South Asians: Focus on the Indian population and its distinct cardiometabolic risk profile","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}